Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.79 |
| ▸ | DRD1 | P21728 | 1/20 | 0.79 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.79 |
| ▸ | PDE4A | P27815 | 1/20 | 0.79 |
| ▸ | SHH | Q15465 | 1/20 | 0.40 |
| ▸ | NECTIN4 | Q96NY8 | 6/20 | 0.36 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.36 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.35 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.35 |
| ▸ | KCNMB4 | Q86W47 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 5/20 | 0.35 |
| ▸ | TSLP | Q969D9 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RXFP4 | Q8TDU9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8227222 | 0.94 | CTSL (0.89) | CTSLDRD1PTGS1PDE4ASHH | |
| SCHEMBL8227043 | 0.94 | CTSL (0.89) | CTSLDRD1PTGS1PDE4ASHH | |
| SCHEMBL8422213 | 0.94 | CTSL (0.88) | CTSLDRD1PTGS1PDE4ASHH | |
| SCHEMBL10157516 | 0.94 | CTSL (0.88) | CTSLDRD1PTGS1PDE4ASHH | |
| SCHEMBL8420524 | 0.94 | CTSL (0.88) | CTSLDRD1PTGS1PDE4ASHH | |
| SCHEMBL8221832 | 0.94 | CTSL (0.88) | CTSLDRD1PTGS1PDE4ASHH | |
| SCHEMBL8227154 | 0.94 | CTSL (0.88) | CTSLDRD1PTGS1PDE4ASHH | |
| SCHEMBL8415773 | 0.94 | CTSL (0.88) | CTSLDRD1PTGS1PDE4ASHH | |
| SCHEMBL21250583 | 0.94 | CTSL (0.88) | CTSLDRD1PTGS1PDE4ASHH | |
| SCHEMBL8415772 | 0.94 | CTSL (0.88) | CTSLDRD1PTGS1PDE4ASHH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335726-B2 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | CUBIST PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7262268-B2 | Lipopeptide stereoisomers, methods for preparing same, and useful intermediates | CUBIST PHARMACEUTICALS, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20060223983-A1 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | CUBIST PHARMACEUTICALS, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223983-A1 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | NGLY1, LSS, NRDC | CTSL 187/4885DRD1 3225/4885PTGS1 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.